

Bulletin from the Extraordinary General Meeting in Magle Chemoswed on 27 November 2020

At the Extraordinary General Meeting in Magle Chemoswed Holding AB (publ) held on 27 November 2020, it was resolved to approve the Board's resolution on a new share issue with pre-emptive rights for the shareholders of SEK 20 million, before transaction costs. Through the rights issue, not more than 800,000 new shares are issued. 25 existing shares entitle to subscription for two new shares. The rights issue is 100 percent covered by free of charge subscription commitments and issue guarantees from existing shareholders.

The subscription price amounts to SEK 25 per share. The record date for participation in the rights issue is 1 December 2020. Subscription for the new shares shall be made during the period 2 – 16 December 2020. The last day of trading in the Magle Chemoswed share including the right to participate in the rights issue is 27 November 2020.

Full terms and conditions for the rights Issue as well as other information about the company will be presented in the Information Memorandum that is expected to be published by the company on 1 December 2020.

For further information, please contact:

Justin Pierce, CEO

Phone: +46 (0)70 593 58 21

Email: Justin.Pierce@maglechemoswed.com

About Us

Magle Chemoswed is a unique international contract development manufacturing company dedicated to bringing ideas to product for customers alongside building our own product pipeline based on our patented technology base. As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Bulletin from the Extraordinary General Meeting in Magle Chemoswed on 27 November 2020](#)